ALKS Alkermes plc.

Q3 2025 10-Q

Filed: Oct 28, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Alkermes plc. (ALKS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue increased $16.0M QoQ, driven by higher product sales, partially offset by lower manufacturing and royalty revenue
• Net income from continuing operations $82.8M vs $92.8M YoY Q3, net income decline of $10.0M

+3 more insights

Risk Factors

• New acquisition risk from Avadel deal pending H1 2026, subject to shareholder, court, and US antitrust approvals
• Most material update: Added $1.2B Bridge Credit Facility for Avadel acquisition, with leverage covenants and default risks

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$394M

▲ +4.2% YoY▲ +0.9% QoQ

Net Income

$83M

▼ -10.4% YoY▼ -5.0% QoQ

Operating Margin

22.6%

▼ -510bp YoY▼ -120bp QoQ

Net Margin

21.0%

▼ -343bp YoY▼ -130bp QoQ

ROE

4.8%

Total Assets

$2.3B

EPS (Diluted)

$0.49

▼ -10.9% YoY▼ -5.8% QoQ

Operating Cash Flow

$102M

▲ +24.6% YoY▼ -32.3% QoQ

Source: XBRL data from Alkermes plc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Alkermes plc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.